{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:05:04Z","timestamp":1761948304040},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T00:00:00Z","timestamp":1509062400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s40261-017-0586-0","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T11:05:42Z","timestamp":1509102342000},"page":"67-77","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece"],"prefix":"10.1007","volume":"38","author":[{"given":"Charalampos","family":"Tzanetakos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Bargiota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Kourlaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Gourzoulidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikos","family":"Maniadakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,27]]},"reference":[{"key":"586_CR1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.diabres.2016.06.018","volume":"118","author":"S Liatis","year":"2016","unstructured":"Liatis S, Dafoulas GE, Kani C, et al. The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database. Diabetes Res Clin Pract. 2016;118:162\u20137.","journal-title":"Diabetes Res Clin Pract"},{"key":"586_CR2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.diabres.2007.09.002","volume":"79","author":"A Gikas","year":"2008","unstructured":"Gikas A, Sotiropoulos A, Panagiotakos D, et al. Rising prevalence of diabetes among Greek adults: findings from two consecutive surveys in the same target population. Diabetes Res Clin Pract. 2008;79:325\u20139.","journal-title":"Diabetes Res Clin Pract"},{"key":"586_CR3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.14310\/horm.2002.1378","volume":"11","author":"N Tentolouris","year":"2012","unstructured":"Tentolouris N, Andrianakos A, Karanikolas G, et al. Type 2 diabetes mellitus is associated with obesity, smoking and low socioeconomic status in large and representative samples of rural, urban, and suburban adult Greek populations. Hormones (Athens). 2012;11:458\u201367.","journal-title":"Hormones (Athens)"},{"key":"586_CR4","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(11)61556-0","volume":"378","author":"A Kentikelenis","year":"2011","unstructured":"Kentikelenis A, Karanikolos M, Papanicolas I, et al. Health effects of financial crisis: omens of a Greek tragedy. Lancet. 2011;378:1457\u20138.","journal-title":"Lancet"},{"key":"586_CR5","unstructured":"International Diabetes Federation. IDF Diabetes atlas 7th ed. Brussels: International Diabetes Federation. 2015. \n                        http:\/\/www.diabetesatlas.org\n                        \n                    . Accessed 1 Feb 2017."},{"key":"586_CR6","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1007\/s00125-002-0861-2","volume":"45","author":"M Koopmanschap","year":"2002","unstructured":"Koopmanschap M. Coping with type II diabetes: the patient\u2019s perspective. Diabetologia. 2002;45:S18\u201322.","journal-title":"Diabetologia"},{"key":"586_CR7","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364\u201379.","journal-title":"Diabetes Care"},{"key":"586_CR8","unstructured":"Hellenic Diabetes Association. Management guidelines for a diabetic patient. \n                        http:\/\/www.ede.gr\/\n                        \n                    . Accessed 15 Sep 2016."},{"key":"586_CR9","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2165\/11209750-000000000-00000","volume":"72","author":"LJ Scott","year":"2012","unstructured":"Scott LJ. Exenatide extended-release: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72:1679\u2013707.","journal-title":"Drugs"},{"key":"586_CR10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/dom.12007","volume":"15","author":"DA Scott","year":"2013","unstructured":"Scott DA, Boye KS, Timlin L, et al. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes Metab. 2013;15:213\u201323.","journal-title":"Diabetes Obes Metab"},{"key":"586_CR11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13300-016-0155-1","volume":"7","author":"S Kayaniyil","year":"2016","unstructured":"Kayaniyil S, Lozano-Ortega G, Bennett HA, et al. A network meta-analysis comparing exenatide once weekly with other GLP-1 receptor agonists for the treatment of type 2 diabetes mellitus. Diabetes Ther. 2016;7:27\u201343.","journal-title":"Diabetes Ther"},{"key":"586_CR12","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1463-1326.2010.01198.x","volume":"12","author":"P McEwan","year":"2010","unstructured":"McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab. 2010;12:623\u201330.","journal-title":"Diabetes Obes Metab"},{"key":"586_CR13","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc07-9919","volume":"30","author":"The Mount Hood 4 Modeling Group","year":"2007","unstructured":"The Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care. 2007;30:1638\u201346.","journal-title":"Diabetes Care"},{"key":"586_CR14","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jval.2013.01.002","volume":"16","author":"AJ Palmer","year":"2013","unstructured":"Palmer AJ, Clarke P, Gray A, et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health. 2013;16:670\u201385.","journal-title":"Value Health"},{"key":"586_CR15","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","volume":"47","author":"PM Clarke","year":"2004","unstructured":"Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747\u201359.","journal-title":"Diabetologia"},{"key":"586_CR16","unstructured":"World Health Organization (WHO). Life tables by country: Greece. \n                        http:\/\/apps.who.int\/gho\/data\/view.main.60640\n                        \n                    . Accessed 15 Mar 2016."},{"key":"586_CR17","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013. \n                        https:\/\/www.nice.org.uk\/article\/pmg9\/chapter\/Foreword\n                        \n                    . Accessed 15 Mar 2016."},{"key":"586_CR18","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","volume":"375","author":"M Diamant","year":"2010","unstructured":"Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234\u201343.","journal-title":"Lancet"},{"key":"586_CR19","unstructured":"NICE (2012) Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes (technology appraisal guidance TA248). \n                        https:\/\/www.nice.org.uk\/guidance\/ta248\n                        \n                    . Accessed 20 Mar 2016."},{"key":"586_CR20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1055\/s-0029-1225338","volume":"117","author":"S Liatis","year":"2009","unstructured":"Liatis S, Thomakos P, Papaoikonomou S, et al. Trends in the management of type 2 diabetes and its prescription drug costs in Greece (1998 and 2006). Exp Clin Endocrinol Diabetes. 2009;117:505\u201310.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"586_CR21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.2040-1124.2011.00187.x","volume":"3","author":"Y Bi","year":"2012","unstructured":"Bi Y, Li X, Yang D, et al. Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: systemic review and meta-analyses. J Diabetes Investig. 2012;3:283\u201393.","journal-title":"J Diabetes Investig"},{"key":"586_CR22","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","volume":"357","author":"RR Holman","year":"2007","unstructured":"Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716\u201330.","journal-title":"N Engl J Med"},{"key":"586_CR23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/dom.12083","volume":"15","author":"L Meneghini","year":"2013","unstructured":"Meneghini L, Kesavadev J, Demissie M, et al. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:729\u201336.","journal-title":"Diabetes Obes Metab"},{"key":"586_CR24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00125-007-0911-x","volume":"51","author":"J Rosenstock","year":"2008","unstructured":"Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51:408\u201316.","journal-title":"Diabetologia"},{"key":"586_CR25","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2337\/dc09-2294","volume":"33","author":"SG Swinnen","year":"2010","unstructured":"Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010;33:1176\u20138.","journal-title":"Diabetes Care"},{"key":"586_CR26","doi-asserted-by":"crossref","unstructured":"Henry RR, Klein EJ, Han J, et al. Efficacy and tolerability of exenatide once weekly over 6\u00a0years in patients with Type 2 Diabetes: an uncontrolled open-label extension of the DURATION-1 Study. Diabetes Technol Ther, 2016;18:677\u201386.","DOI":"10.1089\/dia.2016.0107"},{"key":"586_CR27","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(14)70029-4","volume":"2","author":"M Diamant","year":"2014","unstructured":"Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2014;2:464\u201373.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"586_CR28","unstructured":"Greek Ministry of Health. Drug price bulletin. \n                        http:\/\/www.moh.gov.gr\/\n                        \n                    . Accessed 25 Mar 2016."},{"key":"586_CR29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3111\/13696998.2011.579213","volume":"14","author":"A Beaudet","year":"2011","unstructured":"Beaudet A, Palmer JL, Timlin L, et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ. 2011;14:357\u201366.","journal-title":"J Med Econ"},{"issue":"Suppl 2","key":"586_CR30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3111\/13696998.2012.708691","volume":"15","author":"Y Samyshkin","year":"2012","unstructured":"Samyshkin Y, Guillermin AL, Best JH, et al. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. J Med Econ. 2012;15(Suppl 2):6\u201313.","journal-title":"J Med Econ"},{"key":"586_CR31","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3111\/13696998.2013.803110","volume":"16","author":"T Fonseca","year":"2013","unstructured":"Fonseca T, Clegg J, Caputo G, et al. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index\u00a0\u2265\u00a030\u00a0kg\/m2 in Spain. J Med Econ. 2013;16:926\u201338.","journal-title":"J Med Econ"},{"key":"586_CR32","first-page":"A343","volume":"17","author":"M Charokopou","year":"2014","unstructured":"Charokopou M, Vioix H, Verheggen BG, et al. The impact of long-term clinical evidence on cost-effectiveness of exenatide once weekly (Bydureon\u00ae) versus insulin glargine for patients with type 2 diabetes mellitus (T2DM) from a UK NHS perspective. Value Health. 2014;17:A343.","journal-title":"Value Health"},{"key":"586_CR33","unstructured":"National Organization for Healthcare Services Provision [EOPYY] official website. \n                        http:\/\/www.eopyy.gov.gr\n                        \n                    . Accessed 25 Mar 2016."},{"key":"586_CR34","unstructured":"Government Gazette. Common Ministerial Decree. FEK 1561B\u2019\/21-06-2013."},{"key":"586_CR35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/1472-6963-14-419","volume":"14","author":"C Tzanetakos","year":"2014","unstructured":"Tzanetakos C, Melidonis A, Verras C, et al. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Serv Res. 2014;14:419.","journal-title":"BMC Health Serv Res"},{"key":"586_CR36","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s40261-016-0410-2","volume":"36","author":"C Tzanetakos","year":"2016","unstructured":"Tzanetakos C, Tentolouris N, Kourlaba G, et al. Cost-effectiveness of dapagliflozin as add-on to metformin for the treatment of type 2 diabetes mellitus in Greece. Clin Drug Investig. 2016;36:649\u201359.","journal-title":"Clin Drug Investig"},{"key":"586_CR37","first-page":"628","volume":"30","author":"AK Papazafiropoulou","year":"2013","unstructured":"Papazafiropoulou AK, Kardara MS, Bousboulas S, Pappas SI. Cost of hospitalization for hypoglycemia among subjects with type 2 diabetes. Arch Hell Med. 2013;30:628\u20139.","journal-title":"Arch Hell Med"},{"key":"586_CR38","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s11136-007-9226-0","volume":"16","author":"LS Matza","year":"2007","unstructured":"Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res. 2007;16:1251\u201365.","journal-title":"Qual Life Res"},{"key":"586_CR39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hec.910","volume":"14","author":"A Bagust","year":"2005","unstructured":"Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14:217\u201330.","journal-title":"Health Econ"},{"key":"586_CR40","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1185\/03007995.2014.899207","volume":"30","author":"S Lane","year":"2014","unstructured":"Lane S, Levy AR, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin. 2014;30:1267\u201373.","journal-title":"Curr Med Res Opin"},{"key":"586_CR41","unstructured":"World Health Organization (WHO). Choosing interventions that are cost effective (WHO-CHOICE): cost-effectiveness thresholds. \n                        http:\/\/www.who.int\/choice\/en\/\n                        \n                    . Accessed 25 Sept 2016."},{"key":"586_CR42","unstructured":"International Monetary Fund (IMF). World economic outlook database. \n                        http:\/\/www.imf.org\/external\/pubs\/ft\/weo\/2012\/02\/weodata\/index.aspx\n                        \n                    . Accessed 25 Sept 2016."},{"key":"586_CR43","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/13696998.2016.1203329","volume":"19","author":"LH Chuang","year":"2016","unstructured":"Chuang LH, Verheggen BG, Charokopou M, et al. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. J Med Econ. 2016;19:1127\u201334.","journal-title":"J Med Econ"},{"key":"586_CR44","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.diabet.2013.05.004","volume":"39","author":"J Bodegard","year":"2013","unstructured":"Bodegard J, Sundstrom J, Svennblad B, et al. Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients. Diabetes Metab. 2013;39:306\u201313.","journal-title":"Diabetes Metab"},{"issue":"Suppl 1","key":"586_CR45","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1185\/030079904X1980","volume":"20","author":"AJ Palmer","year":"2004","unstructured":"Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5\u201326.","journal-title":"Curr Med Res Opin"},{"key":"586_CR46","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s12325-014-0166-0","volume":"31","author":"SS Johnston","year":"2014","unstructured":"Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31:1119\u201333.","journal-title":"Adv Ther"},{"key":"586_CR47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/DMSO.S99732","volume":"9","author":"Q Qiao","year":"2016","unstructured":"Qiao Q, Ouwens MJ, Grandy S, et al. Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany. Diabetes Metab Syndr Obes. 2016;9:201\u20135.","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-017-0586-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0586-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0586-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T10:54:25Z","timestamp":1515581665000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-017-0586-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,27]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0586-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,27]]}}}